title: Dual neonate vaccine platform against HIV-1 and M. tuberculosis.
abstract: Acquired immunodeficiency syndrome and tuberculosis (TB) are two of the world's most devastating diseases. The first vaccine the majority of infants born in Africa receive is Mycobacterium bovis bacillus Calmette-Guérin (BCG) as a prevention against TB. BCG protects against disseminated disease in the first 10 years of life, but provides a variable protection against pulmonary TB and enhancing boost delivered by recombinant modified vaccinia virus Ankara (rMVA) expressing antigen 85A (Ag85A) of M. tuberculosis is currently in phase IIb evaluation in African neonates. If the newborn's mother is positive for human immunodeficiency virus type 1 (HIV-1), the baby is at high risk of acquiring HIV-1 through breastfeeding. We suggested that a vaccination consisting of recombinant BCG expressing HIV-1 immunogen administered at birth followed by a boost with rMVA sharing the same immunogen could serve as a strategy for prevention of mother-to-child transmission of HIV-1 and rMVA expressing an African HIV-1-derived immunogen HIVA is currently in phase I trials in African neonates. Here, we aim to develop a dual neonate vaccine platform against HIV-1 and TB consisting of BCG.HIVA administered at birth followed by a boost with MVA.HIVA.85A. Thus, mMVA.HIVA.85A and sMVA.HIVA.85A vaccines were constructed, in which the transgene transcription is driven by either modified H5 or short synthetic promoters, respectively, and tested for immunogenicity alone and in combination with BCG.HIVA(222). mMVA.HIVA.85A was produced markerless and thus suitable for clinical manufacture. While sMVA.HIVA.85A expressed higher levels of the immunogens, it was less immunogenic than mMVA.HIVA.85A in BALB/c mice. A BCG.HIVA(222)-mMVA.HIVA.85A prime-boost regimen induced robust T cell responses to both HIV-1 and M. tuberculosis. Therefore, proof-of-principle for a dual anti-HIV-1/M. tuberculosis infant vaccine platform is established. Induction of immune responses against these pathogens soon after birth is highly desirable and may provide a basis for lifetime protection maintained by boosts later in life.
authors: MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
authors: Richard
authors: R
authors: Hopkins
authors: Anne
authors: A
authors: Bridgeman
authors: Joan
authors: J
authors: Joseph
authors: Sarah C
authors: SC
authors: Gilbert
authors: Helen
authors: H
authors: McShane
authors: Tomáš
authors: T
authors: Hanke
references: Eur J Immunol. 2006 Oct;36(10):2595-600
references: 16981180
references: Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S89-97
references: 15285708
references: J Exp Med. 1988 Oct 1;168(4):1211-24
references: 2459295
references: Gene Ther. 2004 Jul;11(13):1068-80
references: 15164090
references: Vaccine. 2009 Sep 25;27(42):5885-95
references: 19654066
references: Nature. 1991 Jun 6;351(6326):456-60
references: 1904554
references: Vaccine. 2009 Jul 30;27(35):4857-66
references: 19520196
references: Infect Immun. 2001 Feb;69(2):681-6
references: 11159955
references: Eur J Immunol. 2010 Jan;40(1):279-90
references: 20017188
references: Int J Cancer. 2005 Jan 10;113(2):259-66
references: 15386406
references: PLoS One. 2009;4(4):e5264
references: 19367339
references: BMC Immunol. 2008 Apr 15;9:15
references: 18412969
references: J Biomed Biotechnol. 2010;2010:357370
references: 20617151
references: J Virol. 2009 Jun;83(11):5505-13
references: 19297477
references: Vaccine. 2010 Feb 10;28(6):1547-57
references: 19969118
references: Microbes Infect. 2005 May;7(5-6):962-7
references: 15890555
references: Int J Epidemiol. 1993 Dec;22(6):1154-8
references: 8144299
references: JAMA. 1994 Mar 2;271(9):698-702
references: 8309034
references: Int J Tuberc Lung Dis. 2008 Dec;12(12):1376-9
references: 19017445
references: J Immunol. 2005 Nov 15;175(10):6481-8
references: 16272302
references: J Gen Virol. 2007 Jan;88(Pt 1):1-12
references: 17170430
references: J Virol. 2005 Oct;79(20):12871-9
references: 16188989
references: J Immunol. 2007 Feb 1;178(3):1654-61
references: 17237415
references: J Virol. 2007 Sep;81(17):9408-18
references: 17596303
references: J Virol. 2010 Jun;84(12):5898-908
references: 20375158
references: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):412-21
references: 18209682
references: J Gen Virol. 1992 Mar;73 ( Pt 3):653-60
references: 1372038
references: J Exp Med. 2007 Sep 3;204(9):2187-98
references: 17709425
references: Infect Immun. 2009 Aug;77(8):3364-73
references: 19487476
references: J Immunol. 2003 Aug 1;171(3):1602-9
references: 12874255
references: Biotechniques. 1997 Dec;23(6):1094-7
references: 9421642
references: Vaccine. 2007 Mar 1;25(11):1969-92
references: 17224219
references: Clin Vaccine Immunol. 2010 Jul;17(7):1066-73
references: 20484570
references: Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9
references: 2452443
references: Vaccine. 2009 Dec 11;28(2):474-83
references: 19853074
references: PLoS One. 2007 Oct 03;2(10):e984
references: 17912361
references: J Bacteriol. 1999 Aug;181(16):4780-9
references: 10438745
references: Acta Leprol. 1989;7 Suppl 1:256-7
references: 2503999
references: PLoS One. 2009 Jun 16;4(6):e5934
references: 19529780
references: J Immunol Methods. 2004 Feb 1;285(1):25-40
references: 14871532
references: Nat Med. 2000 Sep;6(9):951-5
references: 10973301
references: Am J Respir Crit Care Med. 2009 Apr 15;179(8):724-33
references: 19151191
references: Vaccine. 1996 Oct;14(15):1451-8
references: 8994321
references: Vaccine. 2009 Jul 16;27(33):4412-23
references: 19500523
references: J Virol. 2010 Aug;84(15):7815-21
references: 20484495
references: Vaccine. 2007 Jan 22;25(6):1132-41
references: 17049414
references: J Immunol. 1993 Apr 1;150(7):3101-7
references: 8454878
references: Nat Med. 2004 Nov;10(11):1240-4
references: 15502839
references: Science. 2010 Aug 13;329(5993):856-61
references: 20616233
references: Infect Immun. 2006 May;74(5):2706-16
references: 16622207
references: J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):169-77
references: 14722451
references: Immunology. 2009 Nov;128(3):381-92
references: 20067538
references: J Virol. 2009 Jul;83(14):7176-84
references: 19420086